{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:55:19Z","timestamp":1767894919405,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T00:00:00Z","timestamp":1475625600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00280-016-3156-x","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T05:51:13Z","timestamp":1475646673000},"page":"1003-1011","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study"],"prefix":"10.1007","volume":"78","author":[{"given":"Wijith","family":"Munasinghe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Stodtmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Tolcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Jalving","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"de Vos-Geelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Bergau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silpa","family":"Nuthalapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacie","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,5]]},"reference":[{"key":"3156_CR1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1179\/ACB.66.1.2062507","volume":"66","author":"V Kruse","year":"2011","unstructured":"Kruse V, Rottey S, De Backer O, Van Belle S, Cocquyt V, Denys H (2011) PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy. Acta Clin Belg 66:2\u20139","journal-title":"Acta Clin Belg"},{"key":"3156_CR2","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.2741\/4188","volume":"18","author":"JF Hilton","year":"2013","unstructured":"Hilton JF, Hadfield MJ, Tran MT, Shapiro GI (2013) Poly(ADP-ribose) polymerase inhibitors as cancer therapy. Front Biosci (Landmark Ed) 18:1392\u20131406","journal-title":"Front Biosci (Landmark Ed)"},{"key":"3156_CR3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.5732\/cjc.011.10111","volume":"30","author":"A Chen","year":"2011","unstructured":"Chen A (2011) PARP inhibitors: its role in treatment of cancer. Chin J Cancer 30:463\u2013471","journal-title":"Chin J Cancer"},{"key":"3156_CR4","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","volume":"13","author":"CK Donawho","year":"2007","unstructured":"Donawho CK, Luo Y, Luo Y et al (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13:2728\u20132737","journal-title":"Clin Cancer Res"},{"key":"3156_CR5","doi-asserted-by":"crossref","unstructured":"Rugo HS, Olopade O, DeMichele A et al (2013) Veliparib\/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: first efficacy results from the I-SPY 2 trial. Cancer Res 73(24 suppl): abstract S5\u201302","DOI":"10.1158\/0008-5472.SABCS13-S5-02"},{"key":"3156_CR6","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1158\/1078-0432.CCR-11-2821","volume":"18","author":"S Kummar","year":"2012","unstructured":"Kummar S, Ji J, Morgan R et al (2012) A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 18:1726\u20131734","journal-title":"Clin Cancer Res"},{"key":"3156_CR7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-14-1552","volume":"21","author":"KA Reiss","year":"2015","unstructured":"Reiss KA, Herman JM, Zahurak M et al (2015) A phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis. Clin Cancer Res 21:68\u201376","journal-title":"Clin Cancer Res"},{"key":"3156_CR8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-015-1733-1","volume":"122","author":"MP Mehta","year":"2015","unstructured":"Mehta MP, Wang D, Wang F et al (2015) Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. J Neuro-Oncol 122:409\u2013417","journal-title":"J Neuro-Oncol"},{"key":"3156_CR9","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72:5588\u20135599","journal-title":"Cancer Res"},{"key":"3156_CR10","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1158\/1541-7786.MCR-15-0191-T","volume":"13","author":"TA Hopkins","year":"2015","unstructured":"Hopkins TA, Shi Y, Rodriguez LE et al (2015) Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res 13:1465\u20131477","journal-title":"Mol Cancer Res"},{"key":"3156_CR11","doi-asserted-by":"crossref","unstructured":"Puhalla S, Beumer JH, Pahuja S et al (2014) Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1\/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt). J Clin Oncol 32(suppl):abstract 2570","DOI":"10.1200\/jco.2014.32.15_suppl.2570"},{"key":"3156_CR12","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.2147\/OTT.S69935","volume":"8","author":"LM Wagner","year":"2015","unstructured":"Wagner LM (2015) Profile of veliparib and its potential in the treatment of solid tumors. Onco Targets Ther 8:1931\u20131939","journal-title":"Onco Targets Ther"},{"key":"3156_CR13","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2005) ICH Harmonised tripartite guideline. The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. E14. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E14\/E14_GGuidelin.pdf . Accessed 1 July 2016"},{"key":"3156_CR14","unstructured":"International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. E14 Implementation Working Group (2015). ICH E14 guideline: the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Questions and answers (R3). http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E14\/E14_Q_As_R3__Step4.pdf . Accessed 1 July 2016"},{"key":"3156_CR15","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.60","volume":"97","author":"B Darpo","year":"2015","unstructured":"Darpo B, Benson C, Dota C et al (2015) Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin Pharmacol Ther 97:326\u2013335","journal-title":"Clin Pharmacol Ther"},{"key":"3156_CR16","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1634\/theoncologist.2012-0466","volume":"18","author":"DJ Lenihan","year":"2013","unstructured":"Lenihan DJ, Kowey PR (2013) Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist 18:900\u2013908","journal-title":"Oncologist"},{"key":"3156_CR17","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00280-015-2876-7","volume":"76","author":"H Mizugaki","year":"2015","unstructured":"Mizugaki H, Yamamoto N, Nokihara H et al (2015) A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin\/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol 76:1063\u20131072","journal-title":"Cancer Chemother Pharmacol"},{"key":"3156_CR18","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1365-2125.2012.04442.x","volume":"75","author":"RR Shah","year":"2013","unstructured":"Shah RR, Morganroth J (2013) ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies. Br J Clin Pharmacol 75:959\u2013965","journal-title":"Br J Clin Pharmacol"},{"key":"3156_CR19","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.ahj.2009.02.020","volume":"157","author":"EP Rock","year":"2009","unstructured":"Rock EP, Finkle J, Fingert HJ et al (2009) Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J 157:827\u2013836.e1","journal-title":"Am Heart J"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3156-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3156-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3156-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T04:35:51Z","timestamp":1568435751000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3156-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["3156"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3156-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,5]]}}}